Immunization with attenuated Plasmodium falciparum sporozoites (PfSPZs) has been shown to be protective against malaria, but the features of the antibody response induced by this treatment remain unclear. To investigate this response in detail, we isolated IgM and IgG monoclonal antibodies from Tanzanian volunteers who were immunized with repeated injection of Sanaria PfSPZ Vaccine and who were found to be protected from controlled human malaria infection with infectious homologous PfSPZs. All isolated IgG monoclonal antibodies bound to P. falciparum circumsporozoite protein (PfCSP) and recognized distinct epitopes in its N terminus, NANP-repeat region, and C terminus. Strikingly, the most effective antibodies, as determined in a humanized mouse model, bound not only to the repeat region, but also to a minimal peptide at the PfCSP N-terminal junction that is not in the RTS,S vaccine. These dual-specific antibodies were isolated from different donors and were encoded by VH3-30 or VH3-33 alleles that encode tryptophan or arginine at position 52. Using structural and mutational data, we describe the elements required for germline recognition and affinity maturation. Our study provides potent neutralizing antibodies and relevant information for lineage-targeted vaccine design and immunization strategies.
Malaria is a serious global health threat that caused 445,000 deaths and 216 million clinical cases in 2016 (ref. 1) . Much of the effort to develop a vaccine against the disease has focused on PfSPZs, the asymptomatic parasite stage that mosquitoes inject into the host's skin to initiate a malaria infection. After entering the skin, PfSPZs migrate to the liver, multiply in hepatocytes and then emerge in the blood, where the parasites cause malaria symptoms and differentiate into sexual stages for transmission. Although natural infection by PfSPZs elicits little or no protective immunity to this stage of the life cycle 2, 3 , subunit or whole-organism vaccines based on PfSPZs can induce robust immune responses [4] [5] [6] . The most advanced malaria vaccine candidate, RTS,S, incorporates part of the P. falciparum circumsporozoite protein (PfCSP), which coats the PfSPZ surface and plays a key role in parasite migration out of the skin, entry into the liver parenchyma and invasion of hepatocytes [7] [8] [9] [10] [11] [12] . Multisite clinical trials in sub-Saharan Africa have shown that RTS,S confers modest and short-lived protection against clinical malaria 10, 13, 14 . An alternative approach that has shown promise is the use of whole attenuated PfSPZs as immunogens. This line of research is based on key early discoveries that immunization with irradiated P. berghei sporozoites protected mice against subsequent challenge 15 and that immunization of humans with bites from >1,000 irradiated mosquitoes carrying PfSPZs conferred sterilizing protection against controlled human malaria infection (CHMI) [16] [17] [18] . These studies have led to efforts to develop a vaccine using whole attenuated PfSPZs 19 , and recent trials have shown that immunization with attenuated PfSPZs was highly protective in malaria-naive volunteers and conferred considerable protection in Malian adults 6, [20] [21] [22] . Although these results are promising, the specific mediators of this protective immune response have yet to be fully elucidated. Studies of the antibody response have mainly investigated polyclonal serum responses to PfSPZs and PfCSP 6, [20] [21] [22] , and high-resolution analysis of the monoclonal antibodies generated through vaccination and of their target antigens on the PfSPZ surface remains to be performed. These experiments could provide useful information for the improvement of whole sporozoite-based vaccines and for the identification of new antigens as candidates for a subunit vaccine as well as to generate tools for prophylaxis of P. falciparum infection.
RESULTS

Malaria-exposed individuals produce robust antibody responses to immunizations with PfSPZ Vaccine
We characterized the antibody response of Tanzanian volunteers living in malaria-endemic regions who were immunized with repeated intravenous injection of irradiated PfSPZs (PfSPZ Vaccine) and then underwent CHMI with live homologous PfSPZs (Sanaria PfSPZ Challenge; Fig. 1a) . The serum concentration of IgM and IgG antibodies that bound to live PfSPZs, as measured through flow cytometry, increased following immunization but did not show a clear association with protection against CHMI (Fig. 1b,c and Supplementary  Fig. 1a,b) . Memory B cells from five protected individuals were immortalized and screened using staining of intact PfSPZs to isolate human monoclonal antibodies against any surface antigen on PfSPZs (Supplementary Fig. 1c) . Most of the IgG monoclonal antibodies bound to PfSPZs with high affinity (Fig. 1d,e) . Interestingly, in the two donors from whom both PfSPZ-specific IgM and IgG monoclonal antibodies were isolated, the IgM antibodies were recovered in much higher numbers (Fig. 1f) . The IgM antibodies were less, but still substantially, mutated than the IgG antibodies, which indicates that they originated from IgM-producing memory B cells (Fig. 1g) . In particular, the finding of an antibody lineage that contains both IgM and IgG members suggests an incomplete switch in this response despite repeated immunization (Supplementary Fig. 1d ). These results demonstrate that immunizations with the PfSPZ Vaccine induce a robust antibody response that retains a considerable IgM component.
PfSPZ-specific monoclonal antibodies exhibit potent neutralizing capacity in vitro and in vivo
To identify the features of the most effective neutralizing monoclonal antibodies produced by the protected individuals, we tested a panel of IgG antibodies in vitro for their capacity to inhibit PfSPZ traversal and invasion of a human hepatocyte cell line (Fig. 2a) . The invasion-inhibitory activity varied among antibodies and was significantly correlated with binding affinity to PfSPZs (Fig. 2b) . A subset of antibodies was further tested in an in vivo model using mice with humanized livers for capacity to protect against natural, mosquito bite-transmitted infection of PfSPZs. Some antibodies, such as MGG3, MGG4, MGH2, MGU10 and MGU12, were very potent, reducing liver burden by up to 98.3%, whereas others, such as MGG8, MGH1, MGH3 and MGU1, were less effective (Fig. 2c) . These findings suggest that in vivo neutralizing activity may be related to the fine specificity of the antibodies.
Highly neutralizing antibodies exhibit dual specificity for NANP and the N-terminus junction of PfCSP and are encoded by shared VH3-30 f genes Next, we set out to identify the target antigens of the monoclonal antibodies. Strikingly, although we used an antigen-agnostic approach to identify antibodies that bound to the PfSPZ surface regardless of specificity, we found that all of the tested antibodies bound to recombinant PfCSP (Fig. 2d,e) , confirming that this is the most immunogenic protein on the PfSPZ surface [23] [24] [25] . To understand the basis for effective neutralization, we mapped the specificity of the monoclonal antibodies using synthetic peptides that covered the N terminus, the NANP-repeat region, the N-terminal junction (the connecting region between the N-terminal domain and NANP repeats) and the C terminus of PfCSP. Binding to the classical NANP repeats (NANP 18 peptide; NANPNANPNANPNANPNA), the PfCSP C terminus, recombinant PfCSP or PfSPZs did not correlate with NP1  NP2  NP3  NP4  NP5  NP6  NP7  NP8  NP9  C1  C2   U  G  V MGG1  MGH2  MGU8  MGG2  MGH3  MGU11  MGG3  MGU1  MGU12  MGG4  MGU10  MGV3   MGG8  MGU3  MGW3  MGH1  MGU5   0  22 Fig. 2a-d) . Interestingly, however, binding to a minimal 15-mer peptide (NPDP 15 ; KQPADGNPDPNANPN) that covered the junction between the N-terminal domain and the NANP repeats was a shared characteristic of the most potent in vivo neutralizing antibodies (Fig. 2f) . These potent antibodies also recognized the NANP 18 peptide, suggesting that the capacity to bind both to the NANP repeats and to the N-terminal junction of PfCSP is the main feature of efficient neutralization. Another distinctive characteristic of the most potent antibodies was that they were encoded by shared Fig. 2e ). Collectively, these data indicate that the most potent antibodies have a dual 15 (measured through half-maximal effective concentration (EC 50 )) with in vivo antibody efficacy (measured through liver-stage parasite burden). A two-tailed Spearman's correlation was performed (from n = 1 representative experiment out of 2). Confidence interval not determined by GraphPad Prism for n < 10. a r t i c l e s specificity and that the same gene family encodes their VH. Importantly, such VH3-30 f antibodies were isolated from four out of five donors, suggesting that these antibodies belong to a public antibody lineage and therefore have the potential to be readily induced by vaccination.
VH3-30 f antibodies acquire dual specificity and high affinity for PfCSP through somatic mutations To investigate the influence of somatic mutations on binding of VH3-30 f antibodies to PfCSP, we focused on two clonally related and highly mutated antibodies, MGU1 and MGU10 (Fig. 3a) . The unmutated common ancestor (UCA) of these antibodies, which carries tryptophan at position 52, was able to bind to PfCSP and PfSPZs with low affinity, whereas the Trp52 to Ser52 substitution, which is commonly encoded by VH3-30 alleles, resulted in loss of binding (Fig. 3b,c) . These findings, in conjunction with the high frequency of Trp52 in IgM sequences and with the identification of putative VH3-30 f alleles carrying a germline sequence encoding Trp52 that were obtained from non-B cells of donors G, U and W ( Supplementary Figs. 3 and 4) , identify VH3-30 f alleles encoding Trp52 as preferred alleles for the initiation of this lineage-specific antibody response to PfCSP. The branch point of this clone achieved high-affinity binding, conferred through several mutations, to PfSPZs, PfCSP and NANP 18 , whereas additional mutations in the gene encoding MGU10, but not MGU1, increased breadth through conferring the unique ability to bind to NPDP 15 ( Fig. 3b-e and Supplementary  Fig. 5 ). Despite their similarities in binding to PfSPZs, PfCSP and NANP 18 , MGU10 was substantially more potent than MGU1 in the in vivo assay (Fig. 2c) , suggesting that acquisition of binding to NPDP 15 is the key factor for potent neutralization. Interestingly, mutagenesis studies of MGU10 suggest that Trp52 remains a critical residue for binding to NPDP 15 but becomes dispensable for highaffinity binding to NANP and PfCSP in the fully mutated antibody (Fig. 3f) . In contrast, in a second clonal family consisting of MGU5 and MGU8, high-affinity binding to PfCSP, NANP 18 , NPDP 15 and PfSPZs was already achieved by the branch point, and the remaining mutations in the underlying gene appeared to have no impact on binding ( Supplementary Fig. 6a- 
e).
Unmutated VH3-30 f antibodies recognize PfCSP NANP-repeat units and subsequently acquire binding to specific motifs in the N-terminal junction To investigate the original specificities of VH3-30 f antibodies, we analyzed binding of the UCAs of various VH3-30 f antibodies to PfCSP peptides using a more sensitive bead-based assay. Most UCAs bound to NANP 18 but not to NPDP 15 , suggesting that the antibodies generally started as NANP-specific and gained affinity for NPDP 15 through somatic mutations ( Supplementary Fig. 6f-m) . These data delineate a pathway of antibody development that is dependent on specific alleles encoding the VH and that leads to antibodies with dual specificity. To identify the minimal residues recognized by antibodies at the PfCSP N-terminal junction, we performed a mutational analysis on NPDP 19 (KQPADGNPDPNANPNVDPN), a 19-mer version of NPDP 15 that was used to provide a longer scaffold for binding (Fig. 3g) . The loss of binding to certain peptides identified a specific motif (DPNANP) that was recognized by most antibodies regardless of the gene encoding the VH. These findings, combined with data from peptide-array experiments (Supplementary Fig. 7) , identify the binding site at the N-terminal junction for the most potent neutralizing antibodies as including the first unit of the NANP-repeat region and Concentration (ng/ml) flanking nonrepeat sequences, providing a molecular basis for the dual specificity of these antibodies.
Structural analysis of the MGG4 antibody reveals the basis for recognition of the PfCSP N-terminal junctional peptide To gain structural insights into the recognition of the N-terminal junction, we attempted to crystallize several VH3-30 f antibodies and successfully crystallized MGG4 in complex with the N-1 KQPADGNPDPNANP 14 -C peptide ( Fig. 4a and Supplementary Table 2 ). Only the C-terminal half (NPDPNAN, residues 7-13) of the peptide was visible, with most of the contacts being made by heavychain residues, as evidenced by the antigen-binding fragment-buried surface area (Fig. 4b) . Specifically, the heavy-chain complementaritydetermining region (CDR) loops formed a groove in which the peptide resided ( Fig. 4a and Supplementary Fig. 8a ). In addition, three interfacial waters were involved in an extensive hydrogen-bonding network that connected the side chain of Asn11 to the base of CDR H1 and CDR H3 (Supplementary Fig. 8b ). The CH-π interaction between Pro10 and Trp52 ( Fig. 4a and Supplementary Fig. 8b ) confirmed that the latter residue was critical for binding, as indicated by results from the mutagenesis experiments. Although most peptide residues, except for Asn13, displayed a relatively large buried surface area (Fig. 4c) , weak electron density for the residues visible at the peptides' termini (Asn7, Pro8, Ala12 and Asn13; Fig. 4e and Supplementary Fig. 8c ) indicated structural flexibility and highlighted the DPN sequence as the principal binding motif. Interestingly, the DPN sequence displayed a pseudo 3 10 turn, which was stabilized through hydrogen bonding of the aspartate side chain to the asparagine backbone amide. Such a conformation is very similar to turns observed for unbound NANP-repeat peptides in solution and in the crystal structures of free and antibody-bound peptides (Fig. 4d) [25] [26] [27] [28] [29] . An isolated DPN motif was also present in the C-terminal peptide (residues 282-383), which may explain its binding to MGG4 (Fig. 2e) , notwithstanding the significant differences between the DPN flanking residues in the C-terminal (residues 282-383) and the N-terminal junctional peptides (NDPNR versus PDPNA, respectively). Binding to both NPDP and NANP repeats suggests that the aspartate residue in the DPN motif is interchangeable with an asparagine. Studies on binding of MGG4 to NPDP 19 peptide mutants validate the specificity of MGG4 for DPN and NPN motifs (Fig. 3g) . MGG4 binding was completely abrogated only when the central DPN and NPN motifs within the NPDP 19 peptide were mutated to DPA and AAN. In contrast, a third DPN motif present in the C terminus of the NPDP 19 peptide did not contribute to binding, possibly indicating the importance of flanking residues for optimal binding. Overall, these data imply that potential peptide-binding promiscuity allows MGG4 to bind to diverse epitopes on PfCSP. As other VH3-30 f antibodies cannot bind to the C-terminal peptide (residues 282-383), we expect that they will be less promiscuous and bind to slightly larger or more specific sequences.
Immunization of mice with the NPDP 19 peptide generates a robust but noninhibitory anti-PfSPZ response The finding that the most potent monoclonal antibodies recognize a defined N-terminal junctional peptide suggests that this region could be a component of an effective subunit vaccine. In an initial attempt to investigate whether the NPDP 19 peptide might be sufficient to induce a protective response, we immunized BALB/c mice with NPDP 19 conjugated to keyhole limpet hemocyanin (KLH). All mice produced IgG antibodies that were specific for the NPDP 19 peptide but were at best weakly reactive for the NANP 18 peptide (Supplementary Fig. 9a,b) . Strikingly, in spite of their ability to bind to PfSPZs, the antibodies in mouse serum were unable to inhibit PfSPZ invasion of a hepatocyte cell line in vitro, suggesting that dual specificity for NANP and the N-terminal junction may be required for the potent neutralizing function ( Supplementary Fig. 9c,d) . The finding that the dual-specific antibodies we isolated are encoded by specific human VH3-30 f alleles 32 . Strikingly, all of the IgG antibodies that we identified recognized PfCSP, consistent with previous studies describing the immunodominance of this protein and its abundance on the PfSPZ surface [23] [24] [25] 33, 34 . Our findings are in agreement with previous work that separately describes the importance of the NANP-repeat region of PfCSP and of its N terminus 23, [35] [36] [37] , but notably they highlight the fact that antibodies that target epitopes in both regions simultaneously are more potent than antibodies that exclusively recognize each individual site. Interestingly, the structural analysis and data on mutant peptides indicate that these antibodies, which are originally specific for NANP motifs, do not acquire a completely unrelated specificity, but rather gain promiscuity for sequences centered on a DPN motif. This dual specificity is to a large extent encoded by VH3-30 f alleles but also requires extensive somatic mutations. The importance of dual specificity is highlighted by the fact that immunization with a single NPDP 19 peptide is not sufficient to confer protection despite eliciting production of PfSPZ-binding antibodies. The increased potency of the dual-specific antibodies could be due to the proximity of the N-terminal junction to region I (KLKQP) of PfCSP, which is involved in the cleavage of the N terminus to allow PfSPZ invasion of hepatocytes 9, 12 . This N-terminal junction region is not included in the most advanced malaria vaccine candidate RTS,S, which may explain its limited efficacy in malaria-endemic regions 10 . These findings support continued work to develop whole-PfSPZ vaccines, which contain the entire PfCSP, and provide a rationale for further attempts to develop refined vaccination approaches to elicit dual-specific antibodies using prime-boost strategies with improved carriers 38, 39 .
The finding that the most potent antibodies have a VH encoded by shared genes in multiple donors suggests that these antibodies are part of a public response that can be readily induced by vaccination. These results are reminiscent of previous work on the use of particular VH-coding genes and their allelic forms in the response to the stem of influenza hemagglutinin 40, 41 and justify further efforts to investigate the role of VH gene polymorphisms in protective antibody responses. Nevertheless, the answers to whether these antibodies are sufficient to protect humans and why some individuals were not protected remain to be established. Possible reasons for the latter include the lack of a VH3-30 f allele, the incomplete maturation of antibodies encoded by VH3-30 f or insufficient production of the potent antibodies. The antibodies described could be used to obtain proof of concept that antibodies alone can be protective in vivo in humans, as previously shown in mice and nonhuman primates [42] [43] [44] and could pave the way for the use of antibodies in the prophylaxis of P. falciparum infection and for the development of improved antibody-based subunit vaccines against malaria.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. Sample collection and preparation. For serum preparation, whole blood was collected in Vacutainer tubes (BD Biosciences) containing clot activators and kept at room temperature until a clot was formed. The tube was centrifuged at 2,000g for 10 min at 22 °C, and the serum fraction was stored at −80 °C. Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood through Ficoll density gradient centrifugation and were resuspended in freezing medium for long-term storage in liquid nitrogen.
Flow cytometry assay for detection of antibody binding to PfSPZs.
Cryopreserved PfSPZs (Sanaria) were thawed and stained with different concentrations of Tanzanian sera or monoclonal antibodies in 3.3× SYBR Green I (ThermoFisher Scientific) for 30 min at 4 °C. The PfSPZs were washed twice using centrifugation at 3,220g for 5 min. Human serum antibody binding was detected using 2.5 µg/ml Alexa Fluor 647-conjugated goat anti-human IgG (Jackson ImmunoResearch, 109-606-170) or Alexa Fluor 647-conjugated goat anti-human IgM (Jackson ImmunoResearch, 109-606-129). Mouse serum antibody binding was detected using 1 µg/ml phycoerythrin (PE)-Cy7-conjugated goat anti-mouse IgG (Biolegend, 405315) or PE-Cy7-conjugated rat anti-mouse IgM (BD Biosciences, 552867). FACS Diva (version 6.2) was used for acquisition of samples and FlowJo (version 10.1) was used for FACS analysis. The PfSPZs were gated on the basis of high fluorescence in the FITC channel. Median fluorescence intensity (MFI) of the PfSPZs in the Alexa Fluor 647 or PE-Cy7 channel was calculated to quantify IgG or IgM binding. The concentration of antibody needed to achieve a MFI of 10,000 (Conc 10,000 ) was calculated through interpolation of binding curves fitted to a sigmoidal curve model (GraphPad Prism 7) as a measure of affinity. The gating strategy can be found in Supplementary Figure 1. B cell immortalization and isolation of monoclonal antibodies. IgM-or IgG-producing memory B cells were isolated from frozen peripheral blood mononuclear cells (PBMCs) through magnetic cell sorting with 0.5 µg/ml anti-CD19-PECy7 antibodies (BD, 341113) and mouse anti-PE microbeads (Miltenyi Biotec, 130-048-081) followed by FACS sorting using 3.75 µg/ml Alexa Fluor 647-conjugated goat anti-human IgG (Jackson ImmunoResearch, 109-606-170), 5 µg/ml Alexa Fluor 647-conjugated goat anti-human IgM (Invitrogen, A21215) and PE-labeled anti-human IgD (used at a 1:40 dilution; BD Biosciences, 555779). As previously described 46, 47 , sorted B cells were immortalized with Epstein-Barr virus (EBV) and plated in single-cell cultures in the presence of CpG-DNA (2.5 µg/ml) and irradiated PBMC-feeder cells. Two weeks postimmortalization, the culture supernatants were tested (at a 2:5 dilution) for binding to PfSPZs through flow cytometry using a no-wash protocol. Briefly, cryopreserved PfSPZs were thawed, stained with the supernatants in 6.25× SYBR Green I for 30 min at room temperature and incubated with 2.5 µg/ml Alexa Fluor 647-conjugated goat anti-human IgG or anti-human IgM for 1 h at 4 °C. Only supernatants that did not bind to control beads were selected to exclude polyreactive antibodies.
In vitro inhibition of PfSPZ invasion and traversal. The ability of monoclonal antibodies and serum to prevent PfSPZ invasion and traversal in vitro was tested as previously described 44, 48 . Briefly, 10 µg/ml of monoclonal antibodies were mixed with freshly dissected sporozoites from a GFP luciferase-expressing P. falciparum NF54 strain (PfGFP-luc) in DMEM containing FITC-dextran, 10% FBS, penicillin-streptomycin, fungizone and L-glutamine and were incubated at 37 °C for 15 min. These PfSPZs were then added to HC04 hepatoma cells plated 1 d prior at 80,000 cells per well in a 96-well plate for a final multiplicity of infection (MOI) of 0.3 (26,000 PfSPZs:80,000 HC04 cells). Plates were then spun at 500g for 3 min, and the PfSPZs were left to infect the cells for 90 min at 37 °C. Cells were then fixed, stained with 10 µg/ml of the monoclonal antibody 2A10 conjugated to AlexaFluor-647 and analyzed through flow cytometry for invaded cells (2A10-AlexaFluor-647 positive) or traversed cells (FITC-dextran positive).
In vivo P. falciparum mosquito bite challenge in mice with a humanized liver. FRG huHep mice were purchased from Yecuris, Inc. and were infected via bite of 50 mosquitos carrying PfGFP-luc sporozoites 16-24 h following intraperitoneal injection of 150 µg/mouse of each monoclonal antibody or human IgG control as described previously 44 . The liver-stage parasite burden was determined through bioluminescent imaging using an IVIS imager at day 6 at the peak of liver burden. Reductions in liver burden were calculated through normalization to the mean liver burden of control mice that were injected with an equivalent dose of human IgG within each bite experiment. Sequence analysis of antibody cDNA. cDNA was synthesized from selected B cell cultures, and both the VH and VL were sequenced as previously described 49 .
The genes that encoded the VH and VL and the number of somatic mutations were determined through analyzing the homology between genes encoding the VH and VL sequences of monoclonal antibodies and that of known genes encoding human V, D and J regions that are in the international immunogenetics information system (IMGT) database (version 3.4.8) 50 . Antibody-coding sequences were amplified and sequenced with primers specific for the V and J regions of the given antibody. Sequences were aligned using Clustal Omega (version 1.2.4) 51 . Sequences of the unmutated common ancestor (UCA) of the VH-and VL-coding genes were inferred with Antigen Receptor Probabilistic Parser (ARPP) UA Inference software, as previously described 52 , or were constructed using IMGT/V-QUEST 50 . Phylogenetic trees were generated with the DNA Maximum Likelihood program (Dnaml) of the PHYLIP package, version 3.69 (refs. 40,53) .
Production of recombinant antibodies and antibody variants. Sequences encoding antibody heavy and light chains were cloned into vectors for expression of human IgG1, Igκ and Igγ, and the chains were expressed following transient transfection of these vectors into Expi293F Cells (ThermoFisher Scientific) using polyethylenimine. Cell lines were routinely tested for mycoplasma contamination. The antibodies were affinity purified through protein A chromatography (GE Healthcare).
X-ray crystallography. The KQPADGNPDPNANP peptide was ordered from Innopep Inc. with a purity of >98% and containing chlorine counterions. These peptides have N-terminal acetylation and C-terminal amidation to eliminate charges at the peptide termini. The MGG4-peptide complex was crystallized from a solution containing MGG4 at 11.4 mg/ml in TBS buffer (50 mM Tris-HCl, 137 mM NaCl, 2.7 mM KCl, pH 8.0) with a 5:1 molar ratio of N-KQPADGNPDPNANP-C peptide to the antigen- 18 and NPDP 15 at a concentration of 22 µg/ml (Supplementary Fig. 6f ).
Surface plasmon resonance assays. Biotinylated NPDP 15 and NANP 18 peptides were diluted (20 nM) in HEPES buffered saline (HBS) (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% surfactant Tween-20). HBS was also used as running buffer. An irrelevant biotinylated 19-mer peptide was used as a control for nonspecific interactions. A NeutrAvidin-immobilized NLC ProteOn sensor chip (Biorad) was preconditioned with an NaCl solution (1 M), and the biotinylated peptides were injected onto the chip. The monoclonal antibodies were diluted in HBS to reach a 50 nM starting concentration, followed by a 1 in 3 serial dilution to allow testing of four additional concentrations (16.7, 5.6, 1.9 and 0.6 nM). The diluted antibodies were injected into the chip; one channel of the chip was injected with HBS and used as reference for the analysis. All injections were made at a flow rate of 100 µl/min. Injection time and dissociation time were 240 s and 900 s, respectively. Each binding interaction of the monoclonal antibodies with the biotinylated peptides was assessed using a ProteON XPR36 instrument (Biorad) and data were processed with ProteOn Manager Software (version 3.1.0.6). The association rate (K a ), dissociation rate (K d ) and equilibrium dissociation constant (K D ) were calculated by applying the Langmuir fit model.
Peptide array analysis.
Peptides with a length of 15 amino acids spanning the entire PfCSP (with a shift of a single amino acid between peptides) were synthesized and coated onto a microarray chip (PEPperMAP Linear Epitope Mapping, PEPperPRINT GmBH). The peptides were incubated with 1 µg/ml monoclonal antibodies for 16 h at 4 °C, followed by incubation with DyLight680-conjugated goat anti-human IgG to detect antibody binding.
Immunization of mice.
Female BALB/c mice (6-9 weeks of age) were obtained from ENVIGO Laboratories. All procedures were performed in accordance with guidelines by the Swiss Federal Veterinary Office and after obtaining ethical approval from the Ufficio Veterinario Cantonale, Bellinzona, Switzerland (approval number, 332016). KLH-conjugated NPDP 19 Life Sciences Reporting Summary. Further information on experimental design and reagents is available in the Life Sciences Reporting Summary.
Data availability. Sequence data of the monoclonal antibodies isolated in this study are deposited in GenBank (MG991529-MG991562). The X-ray structure factors and coordinates have been deposited in the Protein Data Bank (PDB ID: 6BQB).
